Investigational drug · Phase 2
S095018
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-small Cell Lung Cancer (NSCLC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "S095018"
First trial start
2024
Aug 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "S095018", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer (NSCLC)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "S095018" as an intervention, largest first.
- Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Pivotal-lookingActive, not recruiting
Servier Bio-Innovation LLCIndustry
NCT06162572 · 102 participants · Start Aug 7, 2024 · Primary completion Apr 2027
Drug: S095018; S095024 and 5 more · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Detroit, Michigan; Canton, Ohio; Columbus, Ohio · 51 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.
Ghiringhelli F, Kim R, Macarulla T, et al. · J Immunother Cancer 2026
Also in development for Non-small Cell Lung Cancer (NSCLC)
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- H2 receptor antagonistPhase 34 trials
Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer
- H1 receptor antagonistPhase 33 trials
Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.